Established in 2017, we are an advanced surgical Robotics company in the medical device industry, dedicated to the design, development and manufacture of surgical Robotics. The Jingfeng multi-hole endoscopic surgical Robotics MP1000 is our recommended core product, while the Jingfeng single-hole endoscopic surgical Robotics SP1000 is our key product under development. According to Frost & Sullivan, we are the first company in China to complete critical clinical trials of multi-hole and single-hole endoscopic surgical Robotics. Both 1MP1000 and SP1000 are qualified for rapid review of innovative medical devices by the State Drug Administration through the green channel. We received approval from the National Drug Administration to register the MP1000 for urological surgery in December 2022. The Chinese surgical Robotics market is fiercely competitive. According to Frost & Sullivan's data, on the last practical date, we had five companies in China approved multi-hole endoscopic surgery Robotics, but none of the single-hole endoscopic surgical Robotics were approved. In addition to the MP1000 and SP1000, we have five other pipeline products under development. As of the last effective date, we have been granted more than 500 patents and patent applications worldwide. As of the same date, we Hold 48 patents and 54 patent applications relating only to the MP1000, 63 patents and 28 patent applications relating only to the SP1000, and 127 patents and 83 patent applications relating to both the MP1000 and SP1000.